Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results
Organogenesis reported Q2 revenue of $42.8 million, down 58% year-over-year, driven primarily by a 61% drop in Advanced Wound Care product sales. The company posted a net loss of $96.3 million, significantly widening from a $9.4 million loss in the prior year, while cash and equivalents dropped by 50% to $46.8 million.
Key figures
- Revenue
- $42.8 million
- Guidance
- FY26 revenue $179.0M-$215.0M (decline of 62%-68%), lowered from prior guidance of 45%-52% decline
- Revenue Yoy
- -58%
- Net loss
- $96.3 million
- Adjusted ebitda loss
- $34.4 million
- Cash and equivalents
- $46.8 million
- Advanced wound care revenue
- $36.1 million
- Surgical sports medicine revenue
- $6.7 million
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.